A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

To join this study, you would need to have been diagnosed with moderate to severe hidradenitis suppurativa (HS) for at least six months. This means your doctor has identified HS lesions (lumps and inflamed areas) in at least two different parts of your body, and that some of your HS is considered quite active.

There are also some reasons why you might not be able to join. For example, if you have certain infections like Hepatitis B or C, or HIV, or if you show signs of active tuberculosis, you wouldn't be able to participate. This helps keep everyone in the study safe.

If you decide to join this study, you'll be involved for a long time. You'll get the study medicine as injections just under your skin, initially once a week. This will be either lutikizumab or a dummy medicine (placebo) in the first phase of the study. After a few months, everyone will receive lutikizumab, either weekly or every other week.

You'll need to go to regular appointments at a hospital or clinic. These visits will involve various medical checks, blood tests, looking for any side effects, and filling out questionnaires and diaries. This helps the study team understand how the medicine is working and how you're feeling. The study involves several stages, with some participants potentially continuing for over three years (156 weeks) to assess the treatment's long-term effects. This is a bigger commitment than standard care but helps gather important information.